Calidi Biotherapeutics, Inc. CLDI · Stock Open Calidi Biotherapeutics, Inc. in new tab

1.04 USD

Add to portfolio

P/E

0.75

EPS

-36.47

P/B

0.70

ROE

-672.22

Beta

1.33

1M 6M YTD 1Y 2Y 5Y Max

Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Calidi Biotherapeutics, Inc. (CLDI)

Currency: USD

DCF Assumptions

Revenue growth (YoY) 0.10 Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).

EBITDA margin 0.30 Decimal (e.g., 0.30 = 30%).

Capex (% Revenue) 0.04 Decimal (e.g., 0.04 = 4%).

Tax rate 0.20 Decimal (e.g., 0.20 = 20%).

Terminal growth (g, %) 3% Percent number (e.g., 3 = 3%).

Cost of Equity (%) 10% Percent number (e.g., 10 = 10%).

Cost of Debt (%) 5% Percent number (e.g., 5 = 5%).

DCF Result

Fair Value (DCF)

—

Current Price

—

Upside

—

WACC

—

Terminal PV

—

Σ PV of FCFs

—

Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Calidi Biotherapeutics, Inc. Analysis (CLDI)

Official Website Stock

Is Calidi Biotherapeutics, Inc. a good investment? Calidi Biotherapeutics, Inc. (CLDI) is currently trading at 1.04 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.75. This relatively low multiple may signal that Calidi Biotherapeutics, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Calidi Biotherapeutics, Inc. is expected to release its next earnings report on Nov. 17, 2026. The market consensus estimate for Forward EPS is -0.90.

Investor FAQ

Does Calidi Biotherapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Calidi Biotherapeutics, Inc.?

Calidi Biotherapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 17, 2026. The company currently has a trailing EPS of -36.47.

Company Profile

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

Exchange Ticker

CLDI

Trades

Dividend History paid per year (USD)

No dividend history available.

Stock Splits

Split Date	Split Ratio to 1
July 15, 2024	1:10
Aug. 5, 2025	0.08

Fundamentals

2026 © AllInvestView

Twitter YouTube Reddit Feature Requests Changelog Support Pricing Help

Support email: [email protected]

Terms of Service | Privacy Policy

Free Trackers · Dividend Apps · Tax Reporting · UK · Australia · Germany · Guides · Ticker Logos

Stock Directory · Financial Glossary · Portfolio Templates · Top Dividend Stocks · Investing in US · Investing in UK · Import Guides · Stock Comparison · Earnings Recaps

Data disclaimer: AIV (AllInvestView) assumes no liability for the information presented. Users are encouraged to exercise caution and carefully consider the accuracy, completeness, and relevance of the information provided.

It's important to remember that our website should complement your independent market research rather than replace it. The past performance of assets should not be regarded as a guarantee of future results. AllInvestView is not a registered investment advisor or broker/dealer, and the information presented here is for educational and informational purposes only. We value your trust and are committed to providing you with valuable market insights while emphasizing the importance of responsible decision-making in your investment journey.